Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Cilloni

Showing results (121-130 of 193) with videos related to

Pageof 20
Sort By:
Haematologica|March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti, et al.
Journal of Clinical Medicine|June 5, 2020
Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning TechniquesDaniela Cilloni, Jessica Petiti, Valentina Campia, et al.
Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP reportGiovanni Martinelli, Ilaria Iacobucci, Clelia Tiziana Storlazzi, et al.
Cancers|November 13, 2021
Droplet Digital PCR for <i>BCR-ABL1</i> Monitoring in Diagnostic Routine: Ready to Start?Maria Teresa Bochicchio, Jessica Petiti, Paola Berchialla, et al.
American Journal of Hematology|June 5, 2025
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network DatabaseFabio Stagno, Rosalba Cucci, Giovanni Marsili, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.
Haematologica|June 11, 2010
The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working PartyIlaria Iacobucci, Annalisa Lonetti, Francesca Paoloni, et al.
British Journal of Haematology|April 12, 2013
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapyGuido Finazzi, Alessandro M Vannucchi, Vincenzo Martinelli, et al.
Pageof 20

Showing results (121-130 of 193) with videos related to

Sort By:
Pageof 20
Haematologica|March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti, et al.
Journal of Clinical Medicine|June 5, 2020
Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning TechniquesDaniela Cilloni, Jessica Petiti, Valentina Campia, et al.
Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP reportGiovanni Martinelli, Ilaria Iacobucci, Clelia Tiziana Storlazzi, et al.
Cancers|November 13, 2021
Droplet Digital PCR for <i>BCR-ABL1</i> Monitoring in Diagnostic Routine: Ready to Start?Maria Teresa Bochicchio, Jessica Petiti, Paola Berchialla, et al.
American Journal of Hematology|June 5, 2025
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network DatabaseFabio Stagno, Rosalba Cucci, Giovanni Marsili, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.
Haematologica|June 11, 2010
The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working PartyIlaria Iacobucci, Annalisa Lonetti, Francesca Paoloni, et al.
British Journal of Haematology|April 12, 2013
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapyGuido Finazzi, Alessandro M Vannucchi, Vincenzo Martinelli, et al.
Pageof 20